专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009120655A1 INDOLE DERIVATIVES 审中-公开
标题翻译： INDOLE DORIVATIVES
公开(公告)号：WO2009120655A1
公开(公告)日：2009-10-01
申请号：PCT/US2009/038022
申请日：2009-03-24
申请人： H. LUNDBECK A/S , JIANG, Yu , HONG, Sang-Phyo , CHEN, Bin , ELDEMENKY, Eman , HUSAIN, Arifa , WU, Lingyun , LU, Kai , MA, Gil , LABELLE, Marc , MARZABADI, Mohammad , SABIO, Michael , WHITE, Andrew , MAZZA, Christine , PACKIARAJAN, Mathivanan
发明人： JIANG, Yu , HONG, Sang-Phyo , CHEN, Bin , ELDEMENKY, Eman , HUSAIN, Arifa , WU, Lingyun , LU, Kai , MA, Gil , LABELLE, Marc , MARZABADI, Mohammad , SABIO, Michael , WHITE, Andrew , MAZZA, Christine , PACKIARAJAN, Mathivanan
IPC分类号： C07D403/02 , C07D209/04
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要： The present invention relates to indole derivatives which bind to the MCHl receptor. In separate aspects, the subject invention is directed to uses of said compounds in the preparation of a pharmaceutical composition for the treatment of obesity and CNS related disorders and to methods of treating said disorders comprising administering a therapeutically effective amount of a compound of the invention.
摘要翻译：本发明涉及与MCH1受体结合的吲哚衍生物。在单独的方面，本发明涉及所述化合物在制备用于治疗肥胖症和CNS相关疾病的药物组合物中的用途以及治疗所述病症的方法，包括施用治疗有效量的本发明化合物。

2. 发明申请

WO2009137270A2 AZETIDINE DERIVATIVES 审中-公开
标题翻译：次黄嘌呤衍生物
公开(公告)号：WO2009137270A2
公开(公告)日：2009-11-12
申请号：PCT/US2009/041343
申请日：2009-04-22
申请人： H. LUNDBECK A/S , JIANG, Yu , MA, Gil , LU, Kai
发明人： JIANG, Yu , MA, Gil , LU, Kai
IPC分类号： C07D403/14 , C07D205/08 , C07D205/04
CPC分类号： C07D401/14 , C07D403/14
摘要： The present invention relates to azetidine derivatives which bind to the MCH l receptor. In separate aspects, the subject invention is directed to uses of said compounds in the preparation of a pharmaceutical composition for the treatment of metabolic and CNS related disorders and to methods of treating said disorders comprising administering a therapeutically effective amount of a compound of the invention.
摘要翻译：本发明涉及与MCH1受体结合的氮杂环丁烷衍生物。在不同的方面，本发明涉及所述化合物在制备用于治疗代谢和CNS相关病症的药物组合物中的用途，以及治疗所述病症的方法，其包括施用治疗有效量的本发明化合物。

3. 发明申请

WO2006041635A3 ARYLTHIOBENZYLPIPERIDINE DERIVATES 审中-公开
公开(公告)号：WO2006041635A3
公开(公告)日：2006-04-20
申请号：PCT/US2005/033870
申请日：2005-09-21
申请人： H. LUNDBECK A/S , MARZABADI, Mohammad, R. , JIANG, Yu , CHEN, Chien-An , LU, Kai , ANDERSEN, Kim
发明人： MARZABADI, Mohammad, R. , JIANG, Yu , CHEN, Chien-An , LU, Kai , ANDERSEN, Kim
IPC分类号： A61K31/5377 , A61K31/445 , C07D211/06 , C07D413/12
摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

4. 发明申请

WO2005069834A2 4-ARYL PIPERIDINES 审中-公开
公开(公告)号：WO2005069834A2
公开(公告)日：2005-08-04
申请号：PCT/US2005/001131
申请日：2005-01-13
申请人： H. LUNDBECK A/S , MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , DELEON, John, E. , JIANG, Yu , LU, Kai
发明人： MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , DELEON, John, E. , JIANG, Yu , LU, Kai
IPC分类号： C07D211/26
CPC分类号： C07D211/26
摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject’s depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者的抑郁症和/或焦虑的量的本发明化合物。

5. 发明申请

WO2004064764A2 SUBSTITUTED ALKYL AMIDO PIPERIDINES 审中-公开
标题翻译：取代的烷基氨基哌啶
公开(公告)号：WO2004064764A2
公开(公告)日：2004-08-05
申请号：PCT/US2004/000175
申请日：2004-01-06
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , JIANG, Yu , LU, Kai
发明人： MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , JIANG, Yu , LU, Kai
IPC分类号： A61K
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

6. 发明申请

WO2006041636A3 AMINO SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES 审中-公开
公开(公告)号：WO2006041636A3
公开(公告)日：2006-04-20
申请号：PCT/US2005/033891
申请日：2005-09-20
申请人： H.LUNDBECK A/S , MARZABADI, Mohammad, R. , CHEN, Chien-An , YU, Jiang , LU, Kai , ANDERSEN, Kim
发明人： MARZABADI, Mohammad, R. , CHEN, Chien-An , YU, Jiang , LU, Kai , ANDERSEN, Kim
IPC分类号： A61K31/4427 , C07D401/06
摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/ or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

7. 发明申请

WO2004005257A1 SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF 审中-公开
标题翻译：作为MCH1拮抗剂的二级氨基酸治疗剂及其用途
公开(公告)号：WO2004005257A1
公开(公告)日：2004-01-15
申请号：PCT/US2003/021391
申请日：2003-07-03
申请人： SYNAPTIC PHARMACEUTICAL CORPORATIONs , MARZABADI, Mohammad , JIANG, Allen , LU, Kai , CHEN, Chien-An , DELEON, John , WETZEL, John
发明人： MARZABADI, Mohammad , JIANG, Allen , LU, Kai , CHEN, Chien-An , DELEON, John , WETZEL, John
IPC分类号： C07D211/70
CPC分类号： C07D211/26 , C07D401/12
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括给予受试者一定量的有效减少受试者体重的本发明化合物。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者抑郁症和/或焦虑症的本发明化合物。本发明还提供了治疗患有尿失禁的受试者的方法。

8. 发明申请

WO2022016485A1 FRAMEWORK FOR UI AUTOMATION BASED ON GRAPH RECOGNITION TECHNOLOGY AND RELATED METHODS 审中-公开
公开(公告)号：WO2022016485A1
公开(公告)日：2022-01-27
申请号：PCT/CN2020/104020
申请日：2020-07-24
申请人： CITRIX SYSTEMS, INC. , LU, Kai
发明人： LU, Kai
IPC分类号： G06F11/36
摘要： A GUI testing device may be configured to execute a testing state machine for interacting with a software application to generate an initial screen of a GUI. The GUI testing device may be configured to determine a current state in the testing state machine based upon a matching trigger target in the initial screen to a given state. The current state may include an operation, and the operation may associate with a trigger target to operate on. The trigger may include a source state, a destination state, and a trigger target. The operation may include a user input operation, and an operation trigger target. The GUI testing device may be configured to perform the operation on the matching trigger target in the initial screen to generate a next screen of the GUI, and advance from the current state to a next state based upon the trigger.

9. 发明申请

WO2004004714A1 SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF 审中-公开
标题翻译：作为MCH1拮抗剂的螺环哌嗪类药物及其用途
公开(公告)号：WO2004004714A1
公开(公告)日：2004-01-15
申请号：PCT/US2003/021348
申请日：2003-07-03
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , MARZABADI, Mohammad , JIANG, Allen , LU, Kai , CHEN, Chien-An , DELEON, John , WETZEL, John
发明人： MARZABADI, Mohammad , JIANG, Allen , LU, Kai , CHEN, Chien-An , DELEON, John , WETZEL, John
IPC分类号： A61K31/438
CPC分类号： C07D221/20 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D491/10
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括给予受试者一定量的有效减少受试者体重的本发明化合物。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者抑郁症和/或焦虑症的本发明化合物。本发明还提供了治疗患有尿失禁的受试者的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式